An international team confirms in a pioneering phase 3 clinical trial the decisive role of the time of day on the success of anti-tumour immunotherapies.
Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...
When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the ...
Targeted indoor residual spraying focuses insecticide applications on common resting surfaces of Aedes aegypti mosquitoes (an arboviral disease vector) in houses, such as exposed lower sections of ...
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
Can We Offset Local Recurrence in Locally Advanced Non–Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes First-Line Nivolumab Plus Relatlimab Versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results